Company Analysis
Sign in

Cocrystal Pharma, Inc. (COCP)

Nasdaq: COCP · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.1
◀ Past 5.3● Present 3.9▶ Future 6.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

16 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cocrystal Pharma, Inc.’s names, not what it holds today.

Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 1 in 2023
Applications published
20
1 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'12'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
COCRYSTAL PHARMA, INC. its own name
US, as the owner printed on each patent
16 granted
2 published
COCRYSTAL PHARMA, INC. its own name
named as the applicant on its applications, in US
0 granted
17 published
BIOZONE PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 15, 202512,357,631Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replicationPharmaceuticalsCOCRYSTAL PHARMA, INC.
Feb 25, 202512,233,066Combinations of inhibitors of influenza virus replicationPharmaceuticalsCOCRYSTAL PHARMA, INC.
Dec 3, 202412,156,876Formulations of influenza therapeuticsPharmaceuticalsCOCRYSTAL PHARMA, INC.
Jul 16, 202412,037,333Pyridopyrazine and pyridotriazine inhibitors of influenza virus replicationPharmaceuticalsCOCRYSTAL PHARMA, INC.
Sep 12, 202311,752,166Combination therapy for treatment of HCVPharmaceuticalsCOCRYSTAL PHARMA, INC.
May 25, 202111,014,941Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replicationPharmaceuticalsCOCRYSTAL PHARMA, INC.
Mar 16, 202110,947,210Inhibitors of Hepatitis C virus polymerasePharmaceuticalsCOCRYSTAL PHARMA, INC.
Nov 5, 201910,464,914Inhibitors of hepatitis C virus polymerasePharmaceuticalsCOCRYSTAL PHARMA, INC.
Oct 1, 201910,426,762Inhibitors of hepatitis C virus polymerasePharmaceuticalsCOCRYSTAL PHARMA, INC.
Jul 3, 201810,011,629Nucleoside analogs for treatment of the flaviviridae family of viruses and cancerOrganic fine chemistryCOCRYSTAL PHARMA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 17, 20252025/0230161POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZAPharmaceuticalsCOCRYSTAL PHARMA, INC.
Dec 5, 20242024/0398757INHIBITORS FOR CORONAVIRUSESOrganic fine chemistryCOCRYSTAL PHARMA, INC.
Jan 18, 20242024/0018145POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZAOrganic fine chemistryCOCRYSTAL PHARMA, INC.
May 25, 20232023/0159453INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATIONOrganic fine chemistryCOCRYSTAL PHARMA, INC.
May 18, 20232023/0151034PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATIONOrganic fine chemistryCOCRYSTAL PHARMA, INC.
Feb 24, 20222022/0056024PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATIONPharmaceuticalsCOCRYSTAL PHARMA, INC. · patent 12,037,333 granted from it
Feb 17, 20222022/0048897INHIBITORS OF INFLUENZA VIRUS REPLICATIONOrganic fine chemistryCOCRYSTAL PHARMA, INC.
Dec 23, 20212021/0393629FORMULATIONS OF INFLUENZA THERAPEUTICSPharmaceuticalsCOCRYSTAL PHARMA, INC. · patent 12,156,876 granted from it
Nov 18, 20212021/0353629COMBINATIONS OF INHIBITORS OF INFLUENZA VIRUS REPLICATIONPharmaceuticalsCOCRYSTAL PHARMA, INC. · patent 12,233,066 granted from it
Jun 3, 20212021/0161935COMBINATION THERAPY FOR TREATMENT OF HCVPharmaceuticalsCOCRYSTAL PHARMA, INC. · patent 11,752,166 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 2 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton COCP · research, not advice